ProStrakan has a number of exciting products and product opportunities for which we require motivated and like-minded partners to help us realise their global potential.  We would welcome enquiries from interested parties on the opportunities outlined below:

Sancuso
Sancuso is currently in European registration and was launched into the US market in November 2008. ProStrakan has already forged a number of key partnerships for Sancuso (see map), and remains interested to find partners in South America, India and CEE Europe. 

Rectogesic/Cellegesic
Rectogesic is being successfully commercialised by ProStrakan and its existing partners in many global markets.  We are looking for potential partners that can register and commercialise Rectogesic in the USA, Japan and Asian territories, along with Latin American and Canadian markets.

Tostran/FORTESTA
We are looking for potential partners that can register and commercialise Tostran/FORTESTA in Australia and New Zealand.

Estradiol Glucoside
ProStrakan owns global rights to the Estradiol Glucoside (E2G) program.  E2G is a conjugated estradiol in Phase II clinical development that offers a unique, patent-protected alternative to current hormone replacement therapies.    

Trimegestone patch    
The Trim patch is a novel estrogen-progestogen patch combining the benefits of a transdermal formulation with those of a new generation pure progestin, trimegesterone.  The Trim patch is ready to enter a Pivotal Phase IIb trial for HRT and is available for global licensing. 

For more information please contact:

Dr Wayne Bowler
Business Development Director

busdev@prostrakan.com
+44 (0)1896 664000